BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Neurology

Andelyn Biosciences and Tern Therapeutics Partner to Advance Gene Therapy for CLN2 Batten Disease

Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered...

September 08, 2025 | News

South Korea’s Neurophet Signs MoU with InRAD to Advance Global Standards for Alzheimer’s and Dementia Data

Neurophet's AI-based brain imaging analysis solutions to support global standardization of Alzheimer's and other dementia-related data Enhancing dementi...

September 03, 2025 | News

Genentech and Alnylam Advance Zilebesiran into Phase III Outcomes Trial for Hypertension

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 – – ...

September 02, 2025 | News

FDA Approves Subcutaneous Leqembi Iqlik, Ushering in a New Era of Alzheimer’s Treatment

U.S. Food and Drug Administration (FDA) announced its approval of a subcutaneous formulation of Leqembi (lecanemab), branded as Leqembi Iql...

September 01, 2025 | News

Actinogen Confirms Commercial Tablet Formulation Of Xanamem Achieves Therapeutic Blood Levels

Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet form...

August 28, 2025 | News

Otsuka Medical Devices Receives Japan Approval For Paradise Ultrasound Renal Denervation System To Treat Resistant Hypertension

Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) announced that the Paradise™ Ultrasound Renal Denervation (uRDN) system has r...

August 26, 2025 | News

Spain’s Ministry of Health Approves Access To Novocure’s TTFields Therapy For Newly Diagnosed Glioblastoma Patients

Eligible patients can receive TTFields therapy through the Spanish National Health System Novocure announced that Spain’s Ministry of Heal...

August 26, 2025 | News

Lighthouse Pharma Secures $49.2M NIH Grant to Launch Phase 2 Alzheimer’s Trial in the United States

Groundbreaking Clinical Trial to Enroll 300 Patients in Double-Blind, Placebo-Controlled Study of Lysine-Gingipain Inhibitor Lighthouse Pharmaceuticals, a...

August 25, 2025 | News

SineuGene Secures Dual U.S. and China IND Clearances for First-in-Class ALS Gene Therapy SNUG01

SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, anno...

August 18, 2025 | News

Energenesis Completes Phase I Trial of ENERGI-F705PD, a Novel Oral Therapy for Parkinson’s Disease

The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pha...

August 04, 2025 | News

Quanterix Launches First-to-Market p‑Tau 205 and 212 Assays, Expanding Alzheimer’s Biomarker Portfolio

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, announced the first to market, com...

August 01, 2025 | News

Alamar Biosciences and Germany’s DZNE Join Forces to Advance Early Detection of Neurodegenerative Diseases

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced a strategic collaboration with the Germa...

July 31, 2025 | News

Alamar Biosciences and DZNE Join Forces to Advance Neurodegeneration Research with Ultra-Sensitive Proteomics

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease,announced a strategic collaboration with the German...

July 30, 2025 | News

Fujitsu and Acer Medical to Launch AI-Powered Gait Analysis for Early Dementia and Parkinson’s Detection in Taiwan

Fujitsu Limited and Acer Medical Inc., a provider of AI-powered medical imaging and preventative medicine, today announced a collaborative agreement to dev...

July 16, 2025 | News

Stay Connected